Cost Drivers on Syam Adusumilli

The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year

Sun, 01 Mar 2026 00:00:00 +0000

A member starts a biologic for rheumatoid arthritis in month three of the plan year. The drug costs $6,500 per month. By month six, the pharmacy claims for that single member exceed what the plan spent on routine medical care for the other fourteen employees combined. The claims fund, set at $240,000 for the year based on actuarial expectation, is 42 percent consumed by one prescription before anyone else’s medical costs are counted.

Executive Summary: The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.01 — The Cost Drivers
#

Specialty drugs account for 2 to 3 percent of prescription volume in commercially insured populations but consume more than half of total drug spending. For a small group level funded plan, the arithmetic is immediate and structural: one member beginning a biologic for rheumatoid arthritis at $6,500 per month can consume 42 percent of a 15-person plan’s $240,000 annual claims fund before any other medical costs are counted. This is not a rare edge case. It is the recurring exposure that defines specialty drug risk for small groups.

Pregnancy and Childbirth: The Claims Event That Reshapes a Small Group Plan Year

Sun, 01 Mar 2026 00:00:00 +0000

A vaginal delivery in a commercially insured population generates average total healthcare costs of $15,712. A cesarean section generates $28,998. These are averages for uncomplicated deliveries, drawn from the Peterson-KFF Health System Tracker’s analysis of 2021 through 2023 Merative MarketScan claims data for employer-sponsored plans. They do not capture the tail. A NICU admission following a complicated delivery generates average spending of $71,158, with the 90th percentile reaching $161,929 and extreme cases exceeding $1 million. The distance between the average and the tail, a factor of four to sixty, occurs within a single clinical category.

Executive Summary: Pregnancy and Childbirth: The Claims Event That Reshapes a Small Group Plan Year

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.02 — The Cost Drivers
#

An uncomplicated vaginal delivery in employer-sponsored plans generates average total healthcare costs of $15,712. A cesarean section generates $28,998. These are the baseline figures from Peterson-KFF Health System Tracker’s analysis of 2021 through 2023 Merative MarketScan data. The averages do not convey the exposure. A NICU admission following a complicated delivery averages $71,158, with the 90th percentile reaching $161,929 and extreme cases exceeding $1 million. The distance between the floor and the tail, a factor of four to sixty, occurs within a single clinical category.

GLP-1 Drugs: Ozempic, Wegovy, and the Demand That Is Not Going Away

Sun, 01 Mar 2026 00:00:00 +0000

Wegovy carries a list price of $1,349 per month. Ozempic lists at $1,028. At $12,000 to $16,000 annually per member on therapy, these drugs add costs that small group plans never budgeted for and cannot avoid budgeting for now. The member who begins a weight loss prescription in January changes the plan’s economics for the entire year. Three members on GLP-1 therapy in a 15-person plan add 15 to 20 percent to total expected claims.

Executive Summary: GLP-1 Drugs: Ozempic, Wegovy, and the Demand That Is Not Going Away

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.03 — The Cost Drivers
#

Wegovy lists at $1,349 per month. Ozempic lists at $1,028. At $12,000 to $16,000 annually per member on therapy, GLP-1 drugs add costs that small group plans never budgeted for. Three members on GLP-1 therapy in a 15-person plan add 15 to 20 percent to total expected claims. Two years ago, the coverage question was whether to include these drugs at all. The SELECT trial, published in the New England Journal of Medicine in November 2023, ended that debate. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20 percent in adults with cardiovascular disease and obesity without diabetes. A drug with documented mortality reduction is not a lifestyle medication. The coverage question shifted from whether to how.

PCSK9 Inhibitors, Inclisiran, and the Alzheimer's Drug Pipeline: The Next Wave of High-Cost Chronic Therapies

Sun, 01 Mar 2026 00:00:00 +0000

A 58-year-old employee with established cardiovascular disease and elevated LDL despite maximum statin therapy is prescribed evolocumab. The drug costs $5,850 per year at list price. The following quarter, another employee begins lecanemab for early Alzheimer’s disease confirmed by amyloid PET scan. That drug costs $26,500 per year. Neither employee was identified as high-risk at underwriting. Neither will stop therapy voluntarily. The drugs will appear in claims data every month, every plan year, indefinitely.

Executive Summary: PCSK9 Inhibitors, Inclisiran, and the Alzheimer's Drug Pipeline: The Next Wave of High-Cost Chronic Therapies

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.04 — The Cost Drivers
#

PCSK9 inhibitors and anti-amyloid Alzheimer’s therapies represent a cost category that does not fit the existing framework for small group plan design. They are not specialty drugs for rare diseases, where low probability limits aggregate exposure and stop loss is calibrated to absorb the hit. They are chronic therapies for conditions common in aging workforces, priced too high to treat as routine pharmacy spend and too prevalent to treat as catastrophic outliers.

Cell and Gene Therapies: The Million-Dollar Claims That Are No Longer Hypothetical

Sun, 01 Mar 2026 00:00:00 +0000

Kymriah costs $475,000. Yescarta costs $373,000. Breyanzi costs $410,000. Carvykti costs $465,000. Casgevy costs $2.2 million. Roctavian costs $2.9 million. These are not projected pipeline costs. They are current list prices for FDA-approved therapies with claims flowing through commercial insurance today. The drug cost alone does not capture the full exposure. Medicare claims data from 2021 through 2022 documented average total costs for CAR-T therapy of approximately $499,000 per inpatient episode and $413,000 per outpatient episode, including hospitalization, monitoring, and management of adverse effects.

Executive Summary: Cell and Gene Therapies: The Million-Dollar Claims That Are No Longer Hypothetical

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.05 — The Cost Drivers
#

Kymriah costs $475,000. Yescarta costs $373,000. Breyanzi costs $410,000. Carvykti costs $465,000. Casgevy costs $2.2 million. Roctavian costs $2.9 million. These are current list prices for FDA-approved therapies with claims flowing through commercial insurance today. Medicare claims data from 2021 through 2022 documented average total costs for CAR-T therapy of approximately $499,000 per inpatient episode, including hospitalization, monitoring, and management of adverse effects. A single claim at these levels exceeds the annual claims fund for most small group level funded plans. A $2.9 million gene therapy claim in a 25-person plan is not a bad year. It is a structural event.

Biosimilars: The Cost Relief Opportunity Most Level Funded Plans Are Missing

Sun, 01 Mar 2026 00:00:00 +0000

Biosimilars generated $20.2 billion in savings across the U.S. healthcare system in 2024 alone, according to the Association for Accessible Medicines. Cumulative savings since the first biosimilar entered the U.S. market have reached $56.2 billion. The adalimumab (Humira) biosimilar market, where 14 competing products are now available, produced over $200 million in savings from January 2024 through March 2025, averaging $4,505 per patient per year according to Evernorth. The savings are real, documented, and growing.

Executive Summary: Biosimilars: The Cost Relief Opportunity Most Level Funded Plans Are Missing

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.06 — The Cost Drivers
#

Biosimilars generated $20.2 billion in savings across the U.S. healthcare system in 2024, with cumulative savings since the first U.S. market entrant reaching $56.2 billion according to the Association for Accessible Medicines. The adalimumab market alone produced over $200 million in savings from January 2024 through March 2025, averaging $4,505 per patient per year according to Evernorth. As of June 2025, 71 biosimilars had received FDA approval across 19 reference products, with 53 commercially launched. The savings are real, documented, and compounding. Most small group level funded plans have not captured them.

Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore

Sun, 01 Mar 2026 00:00:00 +0000

The MRI costs $1,500. The orthopedic consultation costs $400. The physical therapy course costs $2,400 over twelve sessions. The epidural injection costs $2,800. None of these claims appears in the high-cost claimant report. None triggers stop loss review. None catches the plan sponsor’s attention at renewal.

Across six employees with chronic low back pain, the cumulative annual cost is $42,000. Across three employees progressing toward knee replacement and two toward shoulder surgery, the claims trajectory is worse. In five years, the plan will pay $200,000 in surgical claims that were visible in the imaging and injection patterns years earlier. No one was watching.

Executive Summary: Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.07 — The Cost Drivers
#

Musculoskeletal conditions affect more than half of U.S. working-age adults and cost the healthcare system an estimated $420 billion annually according to Evernorth. The Business Group on Health’s 2025 employer survey found cancer and MSK conditions the top two cost drivers for large employers, with three out of four employers placing MSK in their top two categories. UnitedHealthcare’s analysis of its book of business documented MSK costs to employers at $40.51 per member per month. For a 25-person plan with $300,000 in annual claims, that translates to $45,000 to $60,000 in annual MSK spending. No individual claim in that total draws attention. The aggregate is substantial and invisible.

Mental Health, Substance Use, and Social Isolation: The Cost Drivers Nobody Measures and Every Plan Pays For

Sun, 01 Mar 2026 00:00:00 +0000

The claims data shows a member with poorly controlled diabetes. A1c above 9. Medication fills irregular. Emergency department visit for hyperglycemia. The plan sees a diabetic who is not managing their condition. The plan does not see the untreated depression that caused the member to stop taking their medication.

The claims data shows a member with three emergency department visits in six months, each for vague symptoms that do not resolve. The plan sees unexplained utilization. The plan does not see the substance use disorder generating the visits.

Executive Summary: Mental Health, Substance Use, and Social Isolation: The Cost Drivers Nobody Measures and Every Plan Pays For

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.08 — The Cost Drivers
#

Mental health conditions, substance use disorders, and social isolation do not appear in claims coding as primary drivers. They appear instead as poorly controlled diabetes, unexplained emergency department utilization, and MSK trajectories accelerating toward surgery. They operate through other conditions, amplify utilization that would otherwise be routine, and reinforce each other in a self-compounding cycle. They are the most consequential and least measured cost categories in small group plans.

Chronic Disease Compounding: Diabetes, Hypertension, Obesity, and the Predictable Trajectory Most Plans Watch Happen

Sun, 01 Mar 2026 00:00:00 +0000

Well-managed type 2 diabetes costs $10,000 to $15,000 per year in medical and pharmacy claims. Poorly managed diabetes with complications costs $50,000 to $100,000 or more. The difference is not random variation. It is a predictable trajectory visible in claims data three to five years before high-cost complications arrive. The member whose A1c creeps from 7.2 to 8.5 to 9.8 over four years is not a surprise high-cost claimant when diabetic nephropathy appears. The claims data showed rising lab values, irregular medication fills, declining engagement with primary care. The trajectory was visible. The plan watched it happen.

Executive Summary: Chronic Disease Compounding: Diabetes, Hypertension, Obesity, and the Predictable Trajectory Most Plans Watch Happen

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.09 — The Cost Drivers
#

Well-managed type 2 diabetes costs $10,000 to $15,000 per year in medical and pharmacy claims. Poorly managed diabetes with complications costs $50,000 to $100,000 or more. The American Diabetes Association’s 2022 economic cost study documented that people with diagnosed diabetes have medical expenditures 2.6 times higher than people without, averaging $19,736 per year compared to $7,714. Total U.S. costs of diagnosed diabetes reached $412.9 billion in 2022. The cumulative cost differential between well-managed and poorly managed diabetes over a decade is $300,000 to $500,000 per member, visible in claims data three to five years before high-cost complications arrive.

The Combined Cost Pressure: What the Full Weight of These Drivers Means for a Small Group Level Funded Plan

Sun, 01 Mar 2026 00:00:00 +0000

The nine cost drivers documented in this series operate through different mechanisms, arrive on different timelines, and require different management strategies. Treating them as a single “rising costs” narrative obscures the specific threats and the specific responses. But treating them as independent risks understates the actual exposure.

The cost drivers converge. They arrive in the same plan year, on the same small risk pool, through the same claims fund. When multiple drivers hit simultaneously, the combined pressure is compounding, not additive. The behavioral and chronic disease drivers amplify each other. The high-cost acute events coincide with elevated baseline spending. The plan year that looked manageable in underwriting becomes catastrophic in claims experience.

Executive Summary: The Combined Cost Pressure: What the Full Weight of These Drivers Means for a Small Group Level Funded Plan

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.SYN — The Cost Drivers
#

The nine cost drivers documented in this series do not arrive in isolation. They converge on the same small risk pool, in the same plan year, through the same claims fund. When multiple drivers hit simultaneously, the combined pressure is compounding, not additive. The behavioral and chronic disease drivers amplify each other. High-cost acute events coincide with elevated baseline spending. The plan year that looked manageable in underwriting becomes catastrophic in experience. This synthesis models that convergence to establish what Series 10 must address.

Drug Pipeline and Cost Reference: Current and Emerging Therapies Affecting Level Funded Plan Economics

Sun, 01 Mar 2026 00:00:00 +0000

This technical document provides reference data on drugs and therapies discussed throughout Series 09. It is designed for periodic update as approvals and pricing change. Data reflects publicly available information as of early 2026.

GLP-1 Receptor Agonists
#

Semaglutide (Ozempic) Manufacturer: Novo Nordisk. Indication: Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes with established heart disease; chronic kidney disease with type 2 diabetes. FDA Status: Approved December 2017; cardiovascular and renal indications expanded October 2025. List Price: $1,028 per month ($12,336 annually); self-pay $349 per month through NovoCare. Novo Nordisk announced list price reduction to $675 per month effective January 1, 2027. Administration: Weekly subcutaneous injection. Plan Design Notes: Prior authorization typical; step therapy through metformin common.

Executive Summary: Drug Pipeline and Cost Reference: Current and Emerging Therapies Affecting Level Funded Plan Economics

Sun, 01 Mar 2026 00:00:00 +0000

LFP-09.TD1 — The Cost Drivers
#

This technical document provides structured reference data on drugs and therapies discussed throughout Series 09, organized by therapeutic category. It is designed for periodic update as FDA approvals and pricing change. Data reflects publicly available information as of early 2026.

The document covers six categories. GLP-1 receptor agonists includes semaglutide (Ozempic and Wegovy, Novo Nordisk) and tirzepatide (Mounjaro and Zepbound, Eli Lilly), with current list prices, approved indications, administration schedules, and the announced Novo Nordisk list price reduction to $675 per month effective January 1, 2027. PCSK9 inhibitors and cardiovascular agents covers evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio), with current pricing following the 2018 reductions and the AmgenNow self-pay channel at $239 per month for evolocumab. Anti-amyloid Alzheimer’s therapies covers lecanemab (Leqembi, $26,500 annually) and donanemab (Kisunla, approximately $32,000 annually), including diagnostic requirements, monitoring protocols, and APOE e4 risk considerations. CAR-T cell therapies and gene therapies list all six commercially available CAR-T products with current prices ranging from $373,000 to $465,000, and four approved gene therapies ranging from $2.2 million to $3.1 million per treatment. The biosimilar section covers adalimumab, infliximab, ustekinumab, and oncology reference products, including PBM private-label distribution channels and documented savings data. A pipeline monitoring section identifies emerging agents, including oral orforglipron, the triple agonist retatrutide, and late-stage gene therapies for hemophilia B and Duchenne muscular dystrophy.

Cost Drivers on Syam Adusumilli

The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year

Executive Summary: The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year

LFP-09.01 — The Cost Drivers #

Pregnancy and Childbirth: The Claims Event That Reshapes a Small Group Plan Year

Executive Summary: Pregnancy and Childbirth: The Claims Event That Reshapes a Small Group Plan Year

LFP-09.02 — The Cost Drivers #

GLP-1 Drugs: Ozempic, Wegovy, and the Demand That Is Not Going Away

Executive Summary: GLP-1 Drugs: Ozempic, Wegovy, and the Demand That Is Not Going Away

LFP-09.03 — The Cost Drivers #

PCSK9 Inhibitors, Inclisiran, and the Alzheimer's Drug Pipeline: The Next Wave of High-Cost Chronic Therapies

Executive Summary: PCSK9 Inhibitors, Inclisiran, and the Alzheimer's Drug Pipeline: The Next Wave of High-Cost Chronic Therapies

LFP-09.04 — The Cost Drivers #

Cell and Gene Therapies: The Million-Dollar Claims That Are No Longer Hypothetical

Executive Summary: Cell and Gene Therapies: The Million-Dollar Claims That Are No Longer Hypothetical

LFP-09.05 — The Cost Drivers #

Biosimilars: The Cost Relief Opportunity Most Level Funded Plans Are Missing

Executive Summary: Biosimilars: The Cost Relief Opportunity Most Level Funded Plans Are Missing

LFP-09.06 — The Cost Drivers #

Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore

Executive Summary: Musculoskeletal Costs: Back, Joint, and Spine Claims and the Compounding Problem Most Plans Ignore

LFP-09.07 — The Cost Drivers #

Mental Health, Substance Use, and Social Isolation: The Cost Drivers Nobody Measures and Every Plan Pays For

Executive Summary: Mental Health, Substance Use, and Social Isolation: The Cost Drivers Nobody Measures and Every Plan Pays For

LFP-09.08 — The Cost Drivers #

Chronic Disease Compounding: Diabetes, Hypertension, Obesity, and the Predictable Trajectory Most Plans Watch Happen

Executive Summary: Chronic Disease Compounding: Diabetes, Hypertension, Obesity, and the Predictable Trajectory Most Plans Watch Happen

LFP-09.09 — The Cost Drivers #

The Combined Cost Pressure: What the Full Weight of These Drivers Means for a Small Group Level Funded Plan

Executive Summary: The Combined Cost Pressure: What the Full Weight of These Drivers Means for a Small Group Level Funded Plan

LFP-09.SYN — The Cost Drivers #

Drug Pipeline and Cost Reference: Current and Emerging Therapies Affecting Level Funded Plan Economics

GLP-1 Receptor Agonists #

Executive Summary: Drug Pipeline and Cost Reference: Current and Emerging Therapies Affecting Level Funded Plan Economics

LFP-09.TD1 — The Cost Drivers #

LFP-09.01 — The Cost Drivers
#

LFP-09.02 — The Cost Drivers
#

LFP-09.03 — The Cost Drivers
#

LFP-09.04 — The Cost Drivers
#

LFP-09.05 — The Cost Drivers
#

LFP-09.06 — The Cost Drivers
#

LFP-09.07 — The Cost Drivers
#

LFP-09.08 — The Cost Drivers
#

LFP-09.09 — The Cost Drivers
#

LFP-09.SYN — The Cost Drivers
#

GLP-1 Receptor Agonists
#

LFP-09.TD1 — The Cost Drivers
#